


## Imazodan hydrochloride

## Chemical Properties

CAS No. :	89198-09-4
Formula:	C <sub>13</sub> H <sub>13</sub> ClN <sub>4</sub> O
Molecular Weight:	276.72
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Imazodan hydrochloride (CI-914 HCl) is a potent and selective type III phosphodiesterase inhibitor used in the treatment of chronic congestive heart failure.
Targets(IC50)	PDE

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.6138 mL	18.0688 mL	36.1376 mL
5 mM	0.7228 mL	3.6138 mL	7.2275 mL
10 mM	0.3614 mL	1.8069 mL	3.6138 mL
50 mM	0.0723 mL	0.3614 mL	0.7228 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

- Weishaar RE, et al. New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan. *Cardiovasc Drugs Ther.* 1989 Mar;3(1):29-42.
- Goldberg AD, et al. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group. *Am J Cardiol.* 1991 Sep 1;68(6):631-6.
- Geria T, et al. High-performance liquid chromatographic assay of imazodan, methylparaben and propylparaben in imazodan injection. *J Chromatogr.* 1988 Oct 26;450(3):407-13.
- Jiang YY, et al. [Effects of imazodan and dazoxiben on cAMP levels and PGI<sub>2</sub> production in cultured bovine aortic endothelial cells]. *Zhongguo Yao Li Xue Bao.* 1989 Sep;10(5):421-Chinese.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481